Business Wire

Precision Biologics Successfully Completes Safety Phase and Begins Enrollment in Phase 2 Trial Combining NEO-201 and Pembrolizumab (Keytruda)

BETHESDA, Md.--(BUSINESS WIRE)--Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, announced today the successful completion of the safety phase and ...
FiercePharma

Cytovance Biologics, Inc. and Precision Biologics, Inc. Announce Extension of cGMP Manufacturing Agreement for NEO-102 Drug Product

Oklahoma City, OK (March 25, 2014)-- Cytovance Biologics, Inc., a leading full-service contract manufacturer ("CMO") of mammalian and microbial biologics, is extending its manufacturing agreement with ...
Yahoo Finance

Precision Biologics Announces the United States Patent and Trademark Office (USPTO) has granted a Patent for its Lead Monoclonal Antibody, NEO-201, For Methods and Compositions ...

BETHESDA, Md., July 22, 2024 /PRNewswire/ -- Precision Biologics, Inc. ("Precision"), a clinical-stage immunotherapy and targeted oncology company, announced today that on July 16, 2024, the USPTO ...
PharmiWeb

Precision Biologics Announces Publication Of First-In-Human Phase 1 Clinical Trial With NEO-201

BETHESDA, Md.--(BUSINESS WIRE)--Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, announced today the publication of its first in human Phase I ...
Business Wire

Precision Biologics to Highlight Preclinical Data on NEO-201, a Neoantigen Targeting Antibody in Oral Presentation at the 110th Annual Meeting of the American Association of ...

ROCKVILLE, Md.--(BUSINESS WIRE)--Precision Biologics Inc. today announced an abstract reporting data on the company’s neo-antigen program has been accepted for an oral presentation at the upcoming ...